Zobrazeno 31 - 40
of 235
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Manal F. Abdelmalek, Jeongeun Hyun, Steven R. Patierno, Rebecca Caffrey, Cynthia A. Moylan, Muthana Al Abo, Anna Mae Diehl, Xiyou Zhou, Seh-Hoon Oh, Arun J. Sanyal, Kun Xiang, Rajesh Kumar Dutta, Raquel Maeso-Díaz, Jennifer A. Freedman
Publikováno v:
J Hepatol
Background & Aims Non-alcoholic fatty liver disease (NAFLD), the hepatic correlate of the metabolic syndrome, is a major risk factor for hepatobiliary cancer (HBC). Although chronic inflammation is thought to be the root cause of all these diseases,
Autor:
Mazen Noureddin, Manal F. Abdelmalek
Publikováno v:
Hepatology. 76:295-297
Publikováno v:
Hepatology. 77:E111-E112
Autor:
MICHAEL P. COOREMAN, SVEN FRANCQUE, LUCILE DZEN, PHILIPPE HUOT-MARCHAND, JEAN L. JUNIEN, PIERRE BROQUA, MANAL F. ABDELMALEK
Publikováno v:
Diabetes. 71
Lanifibranor therapy resulted in both NASH resolution and fibrosis reduction in the phase 2b NATIVE study in patients with non-cirrhotic NASH, compared to placebo. PPAR signaling is involved in common pathways of NASH and type 2 diabetes (T2D) . We e
Autor:
Colby Ayers, Kara Wegermann, Vanessa Blumer, Robert W. McGarrah, Ambarish Pandey, Cynthia A. Moylan, Anna Mae Diehl, Tarek Bekfani, Anthony E. Peters, Manal F. Abdelmalek, Marat Fudim, Justin L. Grodin
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 842-848 (2021)
ESC Heart Failure
ESC Heart Failure
Aims Non‐alcoholic fatty liver disease leads to progressive liver fibrosis and appears to be a frequent co‐morbid disease in heart failure with preserved ejection fraction (HFpEF). It is well known that liver fibrosis severity predicts future liv
Autor:
Alisha Mavis, Kara Wegermann, Ayako Suzuki, Cynthia A. Moylan, Anna Mae Diehl, Manal F. Abdelmalek
Publikováno v:
Hepatology. 73:1199-1206
Autor:
Andrew M. Shearer, Yanling Wang, Elizabeth K. Fletcher, Rajashree Rana, Emily S. Michael, Nga Nguyen, Manal F. Abdelmalek, Lidija Covic, Athan Kuliopulos
Publikováno v:
Hepatology (Baltimore, Md.). 76(6)
Insulin resistance and poor glycemic control are key drivers of the development of NAFLD and have recently been shown to be associated with fibrosis progression in NASH. However, the underlying mechanisms involving dysfunctional glucose metabolism an
Autor:
Tianyi Chen, George Dalton, Seh-Hoon Oh, Raquel Maeso-Diaz, Kuo Du, Rachel A. Meyers, Cynthia Guy, Manal F. Abdelmalek, Ricardo Henao, Paolo Guarnieri, Steven S. Pullen, Simon Gregory, Joseph Locker, J. Mark Brown, Anna Mae Diehl
Publikováno v:
Cellular and molecular gastroenterology and hepatology.
Nonalcoholic steatohepatitis (NASH), a leading cause of cirrhosis, strongly associates with the Metabolic Syndrome (MetS), an insulin-resistant pro-inflammatory state that disrupts energy balance and promotes progressive liver degeneration. We aimed
Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD
Autor:
Jiayin Zheng, Anna Mae Diehl, Cynthia D. Guy, Ayako Suzuki, Kara Wegermann, Allison E. Ashley-Koch, Shein-Chung Chow, Andrea D. Coviello, Melanie E. Garrett, Cynthia A. Moylan, Manal F. Abdelmalek
Publikováno v:
Hepatology Communications, Vol 5, Iss 4, Pp 598-607 (2021)
Hepatology Communications
Hepatology Communications
The development of fibrosis in nonalcoholic fatty liver disease (NAFLD) is influenced by genetics, sex, and menopausal status, but whether genetic susceptibility to fibrosis is influenced by sex and reproductive status is unclear. Our aim was to iden
Autor:
Manal F. Abdelmalek, Phillip J. White
Publikováno v:
Clin Liver Dis (Hoboken)
Watch a video presentation of this article Answer questions and earn CME.